HCW Biologics Inc.(HCWB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCWB HCW Biologics Inc.

休市中 08-21 16:00:00 EDT

2.18

+0.06

+2.83%

盘后2.22

+0.04+1.83%

19:34 EDT

最高2.23	最低2.05	成交量5.57万
今开2.16	昨收2.12	日振幅8.49%
总市值400.31万	流通市值359.66万	总股本183.63万
成交额12.01万	换手率3.38%	流通股本164.98万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCWB","market":"US","secType":"STK","nameCN":"HCW Biologics Inc.","latestPrice":2.18,"timestamp":1787342400000,"preClose":2.12,"halted":0,"volume":55698,"hourTrading":{"tag":"盘后","latestPrice":2.22,"preClose":2.18,"latestTime":"19:34 EDT","volume":2032,"amount":4486.2519,"timestamp":1787355268292,"change":0.04,"changeRate":0.018349,"amplitude":0.027523},"delay":0,"changeRate":0.028301886792452855,"floatShares":1649800,"shares":1836300,"eps":-27.184607,"marketStatus":"休市中","change":0.06,"latestTime":"08-21 16:00:00 EDT","open":2.16,"high":2.23,"low":2.05,"amount":120077.83106340001,"amplitude":0.084906,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-27.184607,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1626753600000,"exchange":"NASDAQ","adjPreClose":2.12,"preHourTrading":{"tag":"盘前","latestPrice":2.15,"preClose":2.12,"latestTime":"09:04 EDT","volume":2987,"amount":6651.005043499999,"timestamp":1787317449926,"change":0.03,"changeRate":0.014151,"amplitude":0.127358},"postHourTrading":{"tag":"盘后","latestPrice":2.22,"preClose":2.18,"latestTime":"19:34 EDT","volume":2032,"amount":4486.2519,"timestamp":1787355268292,"change":0.04,"changeRate":0.018349,"amplitude":0.027523},"volumeRatio":0.17137436371249903},"requestUrl":"/m/hq/s/HCWB","defaultTab":"news","newsList":[{"id":"1138405969","title":"HCW Biologics发布2026年第二季度业务、临床进展与财务业绩报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1138405969","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138405969?lang=zh_cn&edition=full","pubTime":"2026-08-15 03:16","pubTimestamp":1786734970,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc.（简称HCW Biologics）正式披露其2026年第二季度业务概览、临床开发最新动态及财务表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","HCWB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163716661","title":"HCW Biologics公司其专有第二代四价T细胞衔接蛋白项目达成关键里程碑，按计划将于2027年上半年启动临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1163716661","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163716661?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:01","pubTimestamp":1784808074,"startTime":"0","endTime":"0","summary":"HCW Biologics公司宣布，其在研的专有第二代四价T细胞衔接蛋白（TCE）项目已达成关键开发里程碑。该项目正稳步推进，计划于2027年上半年启动临床试验。\n这一进展标志着公司在开发新一代免疫疗法方面取得了实质性突破。该TCE项目采用了创新的四价设计，旨在更精准、高效地激活患者自身的T细胞，以靶向并清除癌细胞。\n公司表示，项目团队正按既定时间表高效推进临床前研究工作，为即将到来的临床试验做充分准备。这一里程碑的达成，不仅验证了其技术平台的潜力，也为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161374243","title":"HCW Biologics 根据和解协议于2026年5月26日全额付清欠付Eirgenix的款项 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1161374243","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161374243?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:40","pubTimestamp":1782909625,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会（SEC）提交的文件，HCW Biologics Inc. 已于2026年5月26日，依据双方达成的和解协议，全额支付了其欠付Eirgenix的所有款项。此举标志着两家公司之间相关财务义务的完结。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","HCWB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142804982","title":"HCW Biologics公布IL-2融合免疫疗法HCW9302单药治疗斑秃的1期临床试验初步人体数据积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1142804982","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142804982?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:00","pubTimestamp":1781607645,"startTime":"0","endTime":"0","summary":"HCW Biologics公司宣布，其基于IL-2的融合免疫治疗药物HCW9302作为单药疗法，在针对斑秃的1期临床试验中，初步人体数据读出取得了积极成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176253555","title":"HCW Biologics Inc. 宣布依据纳斯达克规则进行约400万美元的按市价私募配售定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1176253555","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176253555?lang=zh_cn&edition=full","pubTime":"2026-05-21 21:54","pubTimestamp":1779371682,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. 已确定其私募配售的定价细节，此次融资规模约为400万美元。该发行将依据纳斯达克资本市场规则，以按市价方式进行。此项安排旨在为公司提供灵活的融资渠道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194891924","title":"HCW Biologics Inc. 预计2027年下半年完成IND支持性研究并提交HCW11-040新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1194891924","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194891924?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:31","pubTimestamp":1778758280,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. 近日公布了其研发管线的重要预期进展。公司计划在2027年下半年完成针对在研药物HCW11-040的新药临床试验申请支持性研究，并随后正式向监管机构提交IND申请。\n这一时间线标志着该候选药物向临床开发阶段迈出了关键一步。IND支持性研究旨在收集必要的临床前数据，以证明药物的安全性、药理活性以及进一步在人体中进行测试的合理性。顺利完成这些研究并提交申请，是推动HCW11-040进入下一阶段研发的核心环节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCWB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148875531","title":"HCW Biologics Inc. 将于4月25日与I.R. Agency LLC签订250万美元营销咨询协议 - 美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1148875531","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148875531?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:18","pubTimestamp":1777544312,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，生物技术公司HCW Biologics Inc. 计划于4月25日与I.R. Agency LLC正式签署一项价值250万美元的营销咨询服务协议。\n该协议标志着HCW Biologics在强化其市场推广和投资者关系战略方面迈出了重要一步。通过引入专业的外部营销咨询机构，公司旨在提升其品牌知名度并优化产品商业化路径。\n此项合作涉及的资金规模反映了HCW Biologics对市场拓展的重视程度。协议的细节已通过SEC文件公开，符合上市公司信息披露的相关规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HCWB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197209834","title":"HCW Biologics Inc. 协议将于2026年5月1日或前后生效，以公开发行完成为条件 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1197209834","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197209834?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:17","pubTimestamp":1777544235,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，HCW Biologics Inc. 已达成一项协议，该协议预计将于2026年5月1日或前后正式启动。不过，此项协议的执行，明确以该公司成功完成其当前计划中的公开发行（Public Offering）为先决条件。这意味着，只有在公开发行顺利结束之后，协议才会正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149108771","title":"HCW Biologics公布T细胞衔接器项目重大进展：揭示作用机制并验证组织因子作为实体瘤治疗靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1149108771","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149108771?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:35","pubTimestamp":1777289757,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. (简称HCWB) 近日就其T细胞衔接器研发项目发布了重要更新。该公告详细阐释了候选药物的作用机理，同时通过实验数据证实，组织因子（Tissue Factor）可作为治疗实体瘤的有效作用靶点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167604662","title":"HCW Biologics公布2025财年第四季度及全年业务亮点与财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1167604662","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167604662?lang=zh_cn&edition=full","pubTime":"2026-04-01 05:06","pubTimestamp":1774991187,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. 近日披露了2025财年第四季度及全年度的核心业务进展和财务数据。报告期内，公司在研发管线推进、临床合作拓展及商业化布局方面取得关键成果，同时现金流状况与研发投入比例呈现优化趋势。此次披露的财务指标为投资者评估其长期价值提供了重要参照。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCWB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170741138","title":"HCW Biologics Inc.获得HCW11-006融合免疫疗法全球独家授权，潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=1170741138","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170741138?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:53","pubTimestamp":1773748419,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc.已成功完成对HCW11-006的全球独家授权协议，这是一款具有高度潜力的融合免疫疗法药物。该协议的签署标志着公司在免疫治疗领域的战略布局迈出关键一步，有望为未来的产品管线注入强劲动力。HCW11-006作为一种创新的融合免疫疗法，在临床前研究中展现出显著的治疗前景，其独特的作用机制可能为相关疾病患者提供新的治疗选择。此次全球独家授权的达成，不仅巩固了HCW Biologics Inc.在生物制药领域的竞争优势，也为公司后续的研发和商业化进程奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617958593","title":"Hcw Biologics Inc.盘中异动 早盘急速下跌8.33%报0.605美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617958593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2617958593?lang=zh_cn&edition=full","pubTime":"2026-03-04 22:43","pubTimestamp":1772635408,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日22时43分，Hcw Biologics Inc.股票出现波动，股价快速下跌8.33%。截至发稿，该股报0.605美元/股，成交量1.7606万股，换手率0.31%，振幅1.32%。Hcw Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304224328a6a29b99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304224328a6a29b99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HCWB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156059587","title":"HCW Biologics Inc. 收到纳斯达克决定函，重获符合所有持续上市规则资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1156059587","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156059587?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:02","pubTimestamp":1772456528,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. 已成功恢复对纳斯达克所有持续上市规则的合规状态，这一结果已通过纳斯达克官方决定函予以确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCWB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613731785","title":"Hcw Biologics Inc.盘中异动 股价大涨5.94%报0.613美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613731785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613731785?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:32","pubTimestamp":1771857124,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时32分，Hcw Biologics Inc.股票出现波动，股价大幅上涨5.94%。截至发稿，该股报0.613美元/股，成交量5707股，换手率0.17%，振幅0.00%。Hcw Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223204a7163236&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223204a7163236&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","HCWB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518227454","title":"Hcw Biologics Inc.盘中异动 急速下挫5.94%报0.343美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227454","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518227454?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:00","pubTimestamp":1741615237,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时00分，Hcw Biologics Inc.股票出现波动，股价急速跳水5.94%。截至发稿，该股报0.343美元/股，成交量4391股，换手率0.01%，振幅4.46%。Hcw Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220037abf3078a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220037abf3078a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","HCWB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517190600","title":"Hcw Biologics Inc.盘中异动 临近收盘股价大涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517190600","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517190600?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:36","pubTimestamp":1741293412,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日04时36分，Hcw Biologics Inc.股票出现波动，股价快速拉升5.31%。Hcw Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.93%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。HCW9302旨在激活和扩张调节性T细胞，从而使炎症小体失活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307043652abebcfc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307043652abebcfc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517097944","title":"Hcw Biologics Inc.盘中异动 急速下挫6.67%报0.333美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517097944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517097944?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:01","pubTimestamp":1741194064,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时01分，Hcw Biologics Inc.股票出现波动，股价大幅下挫6.67%。截至发稿，该股报0.333美元/股，成交量10.5127万股，换手率0.24%，振幅3.92%。Hcw Biologics Inc.股票所在的生物技术行业中，整体涨幅为1.17%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306010104abe9dd54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306010104abe9dd54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCWB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516365677","title":"Hcw Biologics Inc.盘中异动 早盘股价大跌6.89%报0.354美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516365677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516365677?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:32","pubTimestamp":1741098748,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时32分，Hcw Biologics Inc.股票出现波动，股价急速下跌6.89%。截至发稿，该股报0.354美元/股，成交量2.562万股，换手率0.06%，振幅0.84%。Hcw Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223228a25f04bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223228a25f04bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCWB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634474","title":"Hcw Biologics Inc.盘中异动 股价大跌6.37%报0.356美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634474?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012293,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Hcw Biologics Inc.股票出现异动，股价急速下跌6.37%。截至发稿，该股报0.356美元/股，成交量6144股，换手率0.01%，振幅0.00%。Hcw Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223133a25d3f8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223133a25d3f8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516301322","title":"Hcw Biologics Inc.盘中异动 临近收盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516301322?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:52","pubTimestamp":1740775945,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时52分，Hcw Biologics Inc.股票出现波动，股价大幅下挫5.01%。截至发稿，该股报0.360美元/股，成交量5.9597万股，换手率0.13%，振幅5.36%。Hcw Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.71%。Hcw Biologics Inc.公司简介：HCW Biologics Inc是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过打破慢性低度炎症与与年龄相关疾病之间的联系，延长健康寿命。它已选择了两种分子作为其产品候选药物；HCW9218和HCW9302。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301045225963466d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301045225963466d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCWB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hcwbiologics.com;investors.hcwbiologics.com","stockEarnings":[{"period":"1week","weight":-0.1866},{"period":"1month","weight":-0.3483},{"period":"3month","weight":-0.8743},{"period":"6month","weight":-0.3725},{"period":"1year","weight":-0.8902},{"period":"ytd","weight":-0.6257}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"HCW Biologics Inc.于2018年4月2日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于发现和开发新型免疫疗法，通过中断慢性、低度炎症和与年龄相关的疾病之间的联系来延长健康跨度。该公司认为，与年龄相关的慢性低度炎症或“炎症”是导致几种疾病和状况的重要因素，例如癌症、心血管疾病、糖尿病、神经退行性疾病和自身免疫性疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.07168},{"month":2,"riseRate":0.6,"avgChangeRate":0.016626},{"month":3,"riseRate":0.4,"avgChangeRate":-0.075342},{"month":4,"riseRate":0.4,"avgChangeRate":-0.059982},{"month":5,"riseRate":0.4,"avgChangeRate":0.568693},{"month":6,"riseRate":0.4,"avgChangeRate":-0.183841},{"month":7,"riseRate":0.4,"avgChangeRate":-0.065966},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.074328},{"month":9,"riseRate":0.4,"avgChangeRate":-0.08752},{"month":10,"riseRate":0.4,"avgChangeRate":0.021723},{"month":11,"riseRate":0.2,"avgChangeRate":-0.225966},{"month":12,"riseRate":0.2,"avgChangeRate":-0.149456}],"exchange":"NASDAQ","name":"HCW Biologics Inc.","nameEN":"HCW Biologics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HCW Biologics Inc.(HCWB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供HCW Biologics Inc.(HCWB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"HCW Biologics Inc.,HCWB,HCW Biologics Inc.股票,HCW Biologics Inc.股票老虎,HCW Biologics Inc.股票老虎国际,HCW Biologics Inc.行情,HCW Biologics Inc.股票行情,HCW Biologics Inc.股价,HCW Biologics Inc.股市,HCW Biologics Inc.股票价格,HCW Biologics Inc.股票交易,HCW Biologics Inc.股票购买,HCW Biologics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HCW Biologics Inc.(HCWB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供HCW Biologics Inc.(HCWB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}